Hypophysitis is rare during nivolumab treatment (0.1–0.6%) [5, 20]; it is particularly associated with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) therapy [21]. The gene discussed is CTLA4; the disease is hypophysitis.